Tenofovir alafenamide, emtricitabine, and rilpivirine
Brand: Odefsey®
PBAC's latest decision on Tenofovir alafenamide, emtricitabine, and rilpivirine: Recommended with restriction (2016). Considered for Treatment of human immunodeficiency virus (HIV) in treatment-naïve and treatment-experienced patients.
PBAC outcome
Recommended with restriction
Authority Required
ICER (AUD/QALY)
Cost-min
cost-minimisation analysis
Submissions
1
first 2016
Submissions
1
2016 → 2016
Eligible population
Treatment-naïve and treatment-experienced patients with human immunodeficiency virus (HIV).
Therapy area
Infectious disease
Line of therapy
Any
Evidence base
Cost-minimisation
Primary endpoint
Cost-minimisation
Comparator
Eviplera®
Economic model
Cost-minimisation
ICER note
Cost-minimisation analysis based on drug cost only; no ICER calculated.